In the lat­est twist to IL-6 roller coast­er, Roche's Actem­ra fails PhI­II Covid-19 Vek­lury com­bo tri­al

Roche is adding an­oth­er tal­ly mark to the neg­a­tive col­umn on Actem­ra’s mixed record in Covid-19.

The IL-6 drug failed to meet the pri­ma­ry end­point of REM­DAC­TA, where it was paired with Gilead’s ap­proved an­tivi­ral Vek­lury (remde­sivir) for the treat­ment of pa­tients with se­vere Covid-19 pneu­mo­nia. Adding Actem­ra didn’t im­prove time to hos­pi­tal dis­charge, the com­pa­ny re­port­ed, with­out break­ing down the num­bers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER